Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Journal of endocrinological investigation - 1 Feb 2012

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A

Abstract excerpt

BACKGROUND: Medullary thyroid cancer (MTC) is frequently associated with mutations in the tyrosine kinase Ret and with increased expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2). Motesanib is an investigational, orally administered small molecule antagonist of VEGFR1, 2, and 3; platelet-derived growth factor receptor (PDGFR); Kit; and possibly Ret. AIM: The aim of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Human Umbilical Vein Endothelial Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to Mice, Nude

Share to Niacinamide

Share to Oligonucleotides

Share to Proto-Oncogene Proteins c-ret

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21422803
DOI: 10.3275/7609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tumor activity of motesanib in a medullary thyroid cancer model.PMID 21422803Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Management of medullary thyroid cancer.Semantic proximity Read ↗

BAY 43-9006 inhibition of oncogenic RET mutants.Semantic proximity Read ↗

RET mutation and increased angiogenesis in medullary thyroid carcinomas.Semantic proximity Read ↗

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS MetastasesSemantic proximity Read ↗

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Semantic proximity Read ↗

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.Semantic proximity Read ↗

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Semantic proximity Read ↗

RET kinase inhibitors: a review of recent patents (2012–2015)Semantic proximity Read ↗

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.